Earnings ·
Precision BioSciences reported second quarter 2026 financial results with a net loss of $32.7 million, or $(1.26) per…
DTILPrecision Biosciences Inc
Precision BioSciences reported second quarter 2026 financial results with a net loss of $32.7 million, or $(1.26) per share, driven by a non-cash warrant liability adjustment. The company held $112.4 million in cash as of June 30, 2026, sufficient to fund operations through 2028. In the PBGENE-HBV program, biopsy data showed a 1-log reduction in cccDNA and sustained pgRNA loss in all evaluable patients. The PBGENE-DMD trial is actively recruiting at two sites. Additionally, Precision received a $7.5 million clinical milestone payment from TG Therapeutics and announced executive promotions for Naresh Tanna as CFO and Alex Kelly as COO. Precision BioSciences operates in the biotechnology industry, developing in vivo gene editing therapies using its ARCUS platform.